CY1117879T1 - Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων - Google Patents
Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτωνInfo
- Publication number
- CY1117879T1 CY1117879T1 CY20161100786T CY161100786T CY1117879T1 CY 1117879 T1 CY1117879 T1 CY 1117879T1 CY 20161100786 T CY20161100786 T CY 20161100786T CY 161100786 T CY161100786 T CY 161100786T CY 1117879 T1 CY1117879 T1 CY 1117879T1
- Authority
- CY
- Cyprus
- Prior art keywords
- water
- salt
- crystalline
- acetone
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η εφεύρεση αφορά μια νέα διεργασία για την παραγωγή ή/και καθαρισμό του άλατος της ένωσης (S)-2-[4-(2-φθοροβενζυλοξυ) βενζυλαμινο]προπαναμίδη, δηλ. ραλφιναμίδη, ή του αντίστοιχου R-εναντιομερούς, με μεθανοσουλφονικό οξύ σε υψηλές αποδόσεις και πολύ υψηλή εναντιομερική και χημική καθαρότητα στη μορφή του κρυσταλλικού άνυδρου πολύμορφου το οποίο ταυτοποιείται ως μορφή Α, όπου το εν λόγω άλας είναι κατ' ουσία απαλλαγμένο από προσμίξεις που έχουν γονοτοξική επίδραση, όπως (C1-C5)αλκανυλμεθανοσουλφονικά, και υπολειπόμενους διαλύτες γνωστούς ως πιθανούς προδρόμους αυτών, όπως (C1-C5)αλκανόλες ή εστέρες αυτών με κατώτερα αλκανοϊκά οξέα. Η διεργασία προβλέπει (i) παραγωγή ή/και κρυστάλλωση του άλατος, από νερό, ακετόνη, μια αλειφατική κετόνη 4-5 ατόμων άνθρακα ή μίγματα αυτών με νερό, ή (ii) πολτοποίηση του στερεού άλατος με (α) νερό, (β) ένα μίγμα νερού με ακετόνη ή μια αλειφατική κετόνη 4-5 ατόμων άνθρακα, (γ) ακετόνη, μια αλειφατική κετόνη 4-5 ατόμων άνθρακα ή ένα μίγμα αυτής, ή (iii) έκθεση του στερεού άλατος σε ρεύμα αέρα που έχει υψηλό βαθμό σχετικής υγρασίας, και, όταν το λαμβανόμενο προϊόν αποτελείται συνολικά ή εν μέρει από κρυστάλλους μορφής Η κρυσταλλικού ημιένυδρου ψευδοπολύμορφου, μετατροπή του εν λόγω προϊόντος σε κρυστάλλους άνυδρης μορφής Α μέσω υποβολής αυτού σε αφαίρεση νερού. Η μορφή Η κρυσταλλικού ημιένυδρου ψευδοπολύμορφου της μεθανοσουλφονικής ραλφιναμίδης, ή το R-εναντιομερές αυτής, είναι ένα χρήσιμο ενδιάμεσο για τη λήψη του κρυσταλλικού άνυδρου πολύμορφου Α απαλλαγμένου από τις παραπάνω προσμίξεις που έχουν γονοτοξική επίδραση ή/και υπολειπόμενους διαλύτες γνωστούς ως προδρόμους αυτών, και επιδεικνύει ένα φυσικοχημικό προφίλ που συνεισφέρει σημαντικά πλεονεκτήματα στον σχεδιασμό και ανάπτυξη στερεών μορφών δοσολογίας, συγκεκριμένα, φαρμακοτεχνικών μορφών τροποποιημένης αποδέσμευσης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10161207 | 2010-04-27 | ||
PCT/EP2011/055309 WO2011134763A1 (en) | 2010-04-27 | 2011-04-06 | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers |
EP11714958.3A EP2563355B1 (en) | 2010-04-27 | 2011-04-06 | Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117879T1 true CY1117879T1 (el) | 2017-05-17 |
Family
ID=42634917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100786T CY1117879T1 (el) | 2010-04-27 | 2016-08-10 | Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων |
Country Status (28)
Country | Link |
---|---|
US (2) | US9505708B2 (el) |
EP (1) | EP2563355B1 (el) |
JP (3) | JP5808392B2 (el) |
KR (1) | KR101851118B1 (el) |
CN (2) | CN102858330B (el) |
AR (1) | AR085171A1 (el) |
AU (1) | AU2011246707B2 (el) |
BR (1) | BR112012027623B1 (el) |
CA (1) | CA2794389C (el) |
CY (1) | CY1117879T1 (el) |
DK (1) | DK2563355T3 (el) |
EA (1) | EA021389B1 (el) |
ES (1) | ES2590128T3 (el) |
HK (2) | HK1179881A1 (el) |
HR (1) | HRP20161077T1 (el) |
HU (1) | HUE030504T2 (el) |
IL (1) | IL222532A (el) |
LT (1) | LT2563355T (el) |
ME (1) | ME02509B (el) |
MX (1) | MX342697B (el) |
NZ (2) | NZ700221A (el) |
PL (1) | PL2563355T3 (el) |
PT (1) | PT2563355T (el) |
RS (1) | RS55084B1 (el) |
SI (1) | SI2563355T1 (el) |
SM (1) | SMT201600266B (el) |
TW (1) | TWI492919B (el) |
WO (1) | WO2011134763A1 (el) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102858330B (zh) * | 2010-04-27 | 2015-07-22 | 纽朗制药有限公司 | 用于制备拉非酰胺甲磺酸盐或其r-对映异构体的方法 |
CN103804341B (zh) * | 2012-11-13 | 2018-04-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 酰胺衍生物及其医药用途 |
CN104761531B (zh) * | 2014-01-03 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 镇痛活性化合物及其医药用途 |
CN104292128A (zh) * | 2014-07-01 | 2015-01-21 | 南京正科制药有限公司 | 一种沙芬酰胺晶型a |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
JP4350508B2 (ja) | 2001-09-03 | 2009-10-21 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途 |
EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
JP2006515326A (ja) * | 2003-01-30 | 2006-05-25 | ダイノジェン ファーマシューティカルズ, インコーポレイテッド | 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用 |
AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
KR101233711B1 (ko) | 2003-08-25 | 2013-02-18 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 항염증제로서 유용한 알파-아미노아미드 유도체 |
EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
NZ553970A (en) * | 2004-09-10 | 2010-01-29 | Newron Pharm Spa | Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators |
EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
PL2474521T3 (pl) * | 2006-06-19 | 2017-01-31 | Newron Pharmaceuticals S.P.A. | 2-[4-(3- i 2-fluorobenzyloksy)benzyIoamino]propanoamidy o wysokim stopniu czystości do zastosowania jako leki i preparaty farmaceutyczne je zawierające |
JP5315674B2 (ja) * | 2007-11-19 | 2013-10-16 | セントラル硝子株式会社 | 非水電池用電解液及びこれを用いた非水電池 |
KR101709498B1 (ko) * | 2007-12-11 | 2017-02-23 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 고순도의 2[4(3 또는 2플루오로벤질옥시)벤질아미노]프로판아미드의 제조방법 |
CA2707646C (en) | 2007-12-19 | 2016-09-13 | Newron Pharmaceuticals S.P.A. | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders |
WO2009109334A1 (en) | 2008-03-07 | 2009-09-11 | Newron Pharmaceuticals S.P.A. | (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain |
CN102858330B (zh) * | 2010-04-27 | 2015-07-22 | 纽朗制药有限公司 | 用于制备拉非酰胺甲磺酸盐或其r-对映异构体的方法 |
-
2011
- 2011-04-06 CN CN201180020748.2A patent/CN102858330B/zh active Active
- 2011-04-06 HU HUE11714958A patent/HUE030504T2/en unknown
- 2011-04-06 JP JP2013506566A patent/JP5808392B2/ja active Active
- 2011-04-06 CN CN201510387405.XA patent/CN105037188B/zh active Active
- 2011-04-06 BR BR112012027623-9A patent/BR112012027623B1/pt active IP Right Grant
- 2011-04-06 EA EA201291116A patent/EA021389B1/ru unknown
- 2011-04-06 NZ NZ700221A patent/NZ700221A/en unknown
- 2011-04-06 NZ NZ602648A patent/NZ602648A/en unknown
- 2011-04-06 MX MX2012012093A patent/MX342697B/es active IP Right Grant
- 2011-04-06 RS RS20160665A patent/RS55084B1/sr unknown
- 2011-04-06 WO PCT/EP2011/055309 patent/WO2011134763A1/en active Application Filing
- 2011-04-06 LT LTEP11714958.3T patent/LT2563355T/lt unknown
- 2011-04-06 CA CA2794389A patent/CA2794389C/en active Active
- 2011-04-06 ES ES11714958.3T patent/ES2590128T3/es active Active
- 2011-04-06 PL PL11714958.3T patent/PL2563355T3/pl unknown
- 2011-04-06 KR KR1020127030931A patent/KR101851118B1/ko active IP Right Grant
- 2011-04-06 AU AU2011246707A patent/AU2011246707B2/en active Active
- 2011-04-06 ME MEP-2016-169A patent/ME02509B/me unknown
- 2011-04-06 US US13/643,716 patent/US9505708B2/en active Active
- 2011-04-06 EP EP11714958.3A patent/EP2563355B1/en active Active
- 2011-04-06 DK DK11714958.3T patent/DK2563355T3/en active
- 2011-04-06 SI SI201130927A patent/SI2563355T1/sl unknown
- 2011-04-06 PT PT117149583T patent/PT2563355T/pt unknown
- 2011-04-18 TW TW100113339A patent/TWI492919B/zh active
- 2011-04-25 AR ARP110101401A patent/AR085171A1/es not_active Application Discontinuation
-
2012
- 2012-10-18 IL IL222532A patent/IL222532A/en active IP Right Grant
-
2013
- 2013-06-21 HK HK13107273.8A patent/HK1179881A1/xx unknown
-
2015
- 2015-05-22 JP JP2015104930A patent/JP6345154B2/ja active Active
-
2016
- 2016-02-18 HK HK16101796.6A patent/HK1213872A1/zh unknown
- 2016-08-05 SM SM201600266T patent/SMT201600266B/it unknown
- 2016-08-10 CY CY20161100786T patent/CY1117879T1/el unknown
- 2016-08-24 HR HRP20161077TT patent/HRP20161077T1/hr unknown
- 2016-10-12 US US15/291,202 patent/US9856207B2/en active Active
-
2017
- 2017-05-30 JP JP2017106571A patent/JP6450420B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117879T1 (el) | Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων | |
EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
AR080819A1 (es) | Sintesis estereoselectiva de activos que contienen fosforo | |
MEP34408A (en) | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal | |
BRPI0915692B8 (pt) | compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos | |
MX2013011257A (es) | Proceso para la preparacion de dronedarona por n-butilacion. | |
MA32297B1 (fr) | Procede de preparation de derives d'acide 1-(2-halobiphenyl-4-yl)-cyclopropane carboxylique | |
EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
BR112014014060A2 (pt) | processo para a preparação de travoprosta | |
CL2011000296A1 (es) | Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados. | |
BR112017017066A2 (pt) | método de preparação para praziquantel e compostos intermediários do mesmo | |
EA201201666A1 (ru) | Промежуточные соединения агомелатина и способ их получения | |
FR2926080B1 (fr) | Procede de synthese de derives d'acide hydroxy-bisphosphonique | |
ES2540211T3 (es) | Proceso para preparar una amida de un ácido carboxílico pirazólico | |
ITMI20120311A1 (it) | Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato | |
JP2004511477A (ja) | R(+)α−リポ酸の合成 | |
CA2858126A1 (en) | Synthesis of calebin-a and its biologically active analogs | |
PT1673365E (pt) | Processo para a preparação de z-flupentixol | |
ES2381813T3 (es) | Procedimiento para la preparación de ésteres del ácido 2,3,4,9-tetrahidro-1H-beta-carbolin-3-carboxílico | |
EA202190170A1 (ru) | Способ получения ингибитора бромодомена | |
BR112014029361A2 (pt) | método de produção de ácido tereftálico e seus derivados | |
WO2012070896A3 (en) | Synthetic method of enantiomerically pure 2,2'-dihydroxy-1,1'-binaphthyl-3-carboxylic acid | |
ES2383715T3 (es) | Proceso para producir ácido 2-pipecólico-2',6'-xilidida útil como un producto intermedio para la preparación de anestésicos locales | |
RU2013135374A (ru) | Способ получения кальциевых солей оптически активной [d] или рацемической [d, l] гомопантотеновой кислот | |
JP2017066077A (ja) | イミダゾール−2−カルボン酸エステル誘導体又はその塩の製造方法 |